This session will introduce the TPP concept and explain why this key document is a driver in early drug development. You will gain insights into how the TPP functions both as a communication tool and as a strategic roadmap.

Headline

Robert Hägerkvist has worked as a regulatory consultant in many early drug development projects during his five years at RegSmart. Previously Robert was employed as a clinical assessor at the Swedish medical products agency for ten years. Robert has a MSc Pharm and a PhD in medical cell biology.